Ventura Clinical Trials

Ventura, California 93003

1 studies enrolling now · 35 studies all time

What they study most

Alzheimer Disease, Arthritis, Rheumatoid, Atrial Fibrillation, Autism, Autism Spectrum Disorder, CDI, Cardiovascular Disease, Clostridioides Difficile, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Clostridium Difficile, Clostridium Difficile Infection

Studies at this site

• The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer — Recruiting now
• Fecal Microbiota Transplant National Registry — Recruiting now
• A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD) — Running, not enrolling
• Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis — Stopped early
• Vancomycin and Fecal Microbiota Transplant in a Single Patient With Autism Spectrum Disorder — NO_LONGER_AVAILABLE
• Study of Varespladib in Patients Hospitalized With Severe COVID-19 — Stopped early
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies — Stopped early
• Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout — Completed
• Phase 2 Dose-finding IMU-838 for Ulcerative Colitis — Stopped early
• An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis — Completed
• A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis — Completed
• Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection — Completed
• Efficacy and Safety of Oral BT-11 in Ulcerative Colitis — Completed
• L-glutamine Treatment in Patients With Diverticulosis — Completed
• Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL — Paused
• Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease — Completed
• Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) — Completed
• Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol. — Completed
• Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis — Completed
• GLORIA-AF Registry Program - Second and Third Phases — Completed
• Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer — Stopped early
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease — Stopped early
• Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis — Completed
• A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC) — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events — Completed
• SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis — Completed
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease — Withdrawn before enrolling
• Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira — Completed
• Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis — Completed